LIR Life Sciences Corp.
BBCMF
$0.20
$0.000.00%
OTC PK
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 35.92% | -1,029.82% | -38.43% | 33.98% | -87.96% |
| Total Depreciation and Amortization | -10.00% | 0.00% | 25.00% | -- | -- |
| Total Amortization of Deferred Charges | -199.13% | -- | -- | -- | -- |
| Total Other Non-Cash Items | 95.90% | 500,100.00% | -200.00% | -- | -- |
| Change in Net Operating Assets | 92.05% | -323.97% | 106.67% | -32.17% | 116.22% |
| Cash from Operations | 73.61% | -28,855.00% | 88.60% | 38.64% | -53.76% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -93.21% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Investing | -93.21% | -- | 100.00% | -- | -- |
| Total Debt Issued | -- | -100.00% | -85.71% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -76.50% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -100.00% | 2,931.37% | 118.71% | -163.40% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -115.95% | -114.27% | 993.03% | 55.50% | -208.83% |